MX395336B - Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. - Google Patents

Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.

Info

Publication number
MX395336B
MX395336B MX2018003306A MX2018003306A MX395336B MX 395336 B MX395336 B MX 395336B MX 2018003306 A MX2018003306 A MX 2018003306A MX 2018003306 A MX2018003306 A MX 2018003306A MX 395336 B MX395336 B MX 395336B
Authority
MX
Mexico
Prior art keywords
antibody
pharmaceutical preparation
application
medicine
stable anti
Prior art date
Application number
MX2018003306A
Other languages
English (en)
Other versions
MX2018003306A (es
Inventor
Jie Li
Lianshan Zhang
Piaoyang Sun
Pingping Wang
Weikang Tao
Yan Fang
Zhen Yan
Original Assignee
Suzhou Suncadia Biopharmaceuticals Co Ltd
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Suzhou Suncadia Biopharmaceuticals Co Ltd
Publication of MX2018003306A publication Critical patent/MX2018003306A/es
Publication of MX395336B publication Critical patent/MX395336B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una preparación farmacéutica del anticuerpo anti-PD-1 estable y una aplicación de la misma en un medicamento. La preparación farmacéutica del anticuerpo anti-PD-1 comprende un anticuerpo anti-PD-1, un amortiguador y puede comprender además al menos un tipo de estabilizante, y opcionalmente puede comprender además un tensoactivo. La preparación farmacéutica del anticuerpo anti-PD-1 de la presente invención puede suprimir eficazmente la agregación y desaminación de anticuerpos, evitando de este modo la degradación de un producto de anticuerpo, obteniendo una preparación farmacéutica inyectada estable.
MX2018003306A 2015-09-28 2016-09-14 Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. MX395336B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510629020 2015-09-28
PCT/CN2016/098982 WO2017054646A1 (zh) 2015-09-28 2016-09-14 一种抗pd-1抗体制剂及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2018003306A MX2018003306A (es) 2018-05-16
MX395336B true MX395336B (es) 2025-03-25

Family

ID=58422670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003306A MX395336B (es) 2015-09-28 2016-09-14 Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.

Country Status (13)

Country Link
US (2) US10786567B2 (es)
EP (1) EP3357508A4 (es)
JP (1) JP6921062B2 (es)
KR (1) KR20180054791A (es)
CN (1) CN106999591B (es)
AU (1) AU2016329960A1 (es)
BR (1) BR112018005349A2 (es)
CA (1) CA2999079A1 (es)
MX (1) MX395336B (es)
RU (1) RU2731418C2 (es)
TW (1) TWI721020B (es)
UA (1) UA124259C2 (es)
WO (1) WO2017054646A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CR20160319A (es) * 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
EP3357508A4 (en) 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2766590C2 (ru) 2017-05-16 2022-03-15 Цзянсу Хэнжуй Медисин Ко., Лтд. Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
US11273205B2 (en) * 2017-07-25 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. IL-15 protein complex pharmaceutical composition
CN111132696B (zh) * 2017-10-13 2023-05-16 江苏恒瑞医药股份有限公司 Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN111094339B (zh) * 2017-10-17 2023-01-24 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
CN109793892B (zh) * 2017-11-16 2022-07-26 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
WO2019096194A1 (zh) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
CN111246881B (zh) * 2017-12-14 2023-03-10 江苏恒瑞医药股份有限公司 Pd-1抗体用于治疗肿瘤的用途
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110272491B (zh) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 一种抗pd-1抗体的纯化工艺
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
CN110448691A (zh) * 2018-05-07 2019-11-15 江苏恒瑞医药股份有限公司 抗pd-1抗体联合il-15蛋白复合物在制备治疗肿瘤的药物中的用途
KR20210030366A (ko) 2018-06-20 2021-03-17 인사이트 코포레이션 항-pd-1 항체 및 이의 용도
AU2019323435A1 (en) * 2018-08-20 2021-02-18 Jiangsu Hengrui Medicine Co., Ltd. Use of TIM-3 antibody in preparation of medicines for treating tumors
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7883848B2 (ja) * 2018-11-06 2026-07-02 ジエンス ヘンルイ メデイシンカンパニー リミテッド 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗pd-1抗体の使用
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP7503056B6 (ja) * 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
CN111346225A (zh) * 2018-12-21 2020-06-30 上海张江生物技术有限公司 含有蛋白质的药物制剂
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
EP4077388A1 (en) * 2019-12-18 2022-10-26 Tesaro, Inc. Biopharmaceutical compositions and related methods
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
TW202130367A (zh) * 2020-01-15 2021-08-16 大陸商信達生物製藥(蘇州)有限公司 結合pd-1和pd-l1的雙特異性抗體的製劑及其用途
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CN115279405B (zh) * 2020-04-10 2025-02-18 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途
EP4137155A4 (en) * 2020-04-17 2024-10-30 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. PREPARATION SPECIFICALLY RELATED TO CD137 AND ITS USE
US20230295329A1 (en) * 2020-07-31 2023-09-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-pd-1 antibody pharmaceutical composition and use thereof
CN114099423A (zh) * 2020-08-25 2022-03-01 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1双功能融合蛋白的制剂
US20230365692A1 (en) 2020-09-24 2023-11-16 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
CN114392352A (zh) * 2020-09-27 2022-04-26 广东东阳光药业有限公司 一种稳定的抗pd-1抗体的药物制剂
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
CN115212209B (zh) * 2021-04-19 2023-11-28 中国科学院分子细胞科学卓越创新中心 一种具有免疫佐剂活性和促进免疫疗法的抗肿瘤药物
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
US20240287185A1 (en) 2021-06-23 2024-08-29 Formycon Ag Formulations of anti-pd1 antibodies
US20240366757A1 (en) * 2021-09-07 2024-11-07 Dr. Reddy’S Laboratories Limited Formulations of immune check point inhibitors or like
EP4398931A4 (en) * 2021-09-07 2025-07-16 Dr Reddys Laboratories Ltd IMMUNE CHECKPOINT INHIBITOR FORMULATIONS
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
CN115656496A (zh) * 2022-10-28 2023-01-31 迪瑞医疗科技股份有限公司 一种普适型冻干保护剂及其应用
US20260207493A1 (en) 2022-12-21 2026-07-23 Formycon Ag Formulations of anti-pd1 antibodies
WO2024171082A1 (en) 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Stable protein compositions of anti-pd1 antibody
WO2026133192A1 (en) 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1034292A (zh) * 1988-01-15 1989-07-26 翁文聘 异步整流发电机
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン,エルエルシー タンパク質製剤
CA2647111A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
JP2010531340A (ja) * 2007-07-10 2010-09-24 エフ.ホフマン−ラ ロシュ アーゲー 新規処方物
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
CN102892786B (zh) * 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CR20160319A (es) * 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
US10899840B2 (en) * 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3357508A4 (en) 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE

Also Published As

Publication number Publication date
UA124259C2 (uk) 2021-08-18
JP2018532730A (ja) 2018-11-08
JP6921062B2 (ja) 2021-08-18
TW201711699A (zh) 2017-04-01
AU2016329960A1 (en) 2018-04-26
BR112018005349A2 (pt) 2018-10-09
TWI721020B (zh) 2021-03-11
KR20180054791A (ko) 2018-05-24
EP3357508A1 (en) 2018-08-08
CN106999591A (zh) 2017-08-01
MX2018003306A (es) 2018-05-16
US20180339045A1 (en) 2018-11-29
US20210000954A1 (en) 2021-01-07
CA2999079A1 (en) 2017-04-06
RU2731418C2 (ru) 2020-09-02
WO2017054646A1 (zh) 2017-04-06
RU2018110333A (ru) 2019-10-28
US10786567B2 (en) 2020-09-29
EP3357508A4 (en) 2019-04-24
CN106999591B (zh) 2021-02-23
RU2018110333A3 (es) 2019-12-30

Similar Documents

Publication Publication Date Title
MX2018003306A (es) Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
ZA202303593B (en) Liquid protein formulations containing viscosity-lowering agents
DOP2018000074A (es) Moduladores de la proteína core de la hepatitis b
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
EP3402548C0 (en) OCCLUSION RESOLUTION IN DRUG DELIVERY DEVICES, SYSTEMS, AND METHODS
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
GEP20217243B (en) Orodispersible dosage unit containing an estetrol component
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
EP3318282A4 (en) AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
TW201613557A (en) Stable aqueous recombinant protein formulations
ES3063790T3 (en) Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
MX2022006770A (es) Dispersiones solidas de bendamustina e infusion continua.
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
WO2017079403A3 (en) Polymeric nanoparticles
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2019014666A (es) Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo.
EP3313390A4 (en) INTRAVENOUS ADMINISTRATION OF CITRULLIN DURING SURGICAL PROCEDURE
MX2017013795A (es) Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
GT201600158A (es) Filtros para equipos de infusión
BR112017014295A2 (pt) composição farmacêutica.
AR108280A1 (es) Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo